Μετάβαση στο περιεχόμενο

Potential of First-in-Class Epidiolex for Epilepsy and its Significance in the Advent of Medical Marijuana

image

With the FDA’s landmark approval of Epidiolex, a cannabidiol used to treat rare, severe pediatric epilepsies, the only obstacle to the legal sale of the drug is DEA reclassification of cannabidiol (CBD). With reclassification likely in the next 90 days, what does it mean for the epilepsy market, as well as the wider market for CBD?

Download Potential of First-in-Class Epidiolex for Epilepsy and its Significance in the Advent of Medical Marijuana and Discover:

  • Epidiolex’s potential as a first-in-class drug in the epilepsy market and the first FDA-approved drug for Dravet syndrome
  • Regulatory repercussions in the form of drug scheduling following the first cannabis plant-derived drug to receive FDA approval
  • Biomedtracker analyses, including change to Likelihood of Approval (LOA)
  • In-depth analysis of historical trends and the current global status of cannabinoid drug development for targeted indications
  • Evaluation of important issues pertinent to medicinal cannabinoid development and its potential to successfully address the opioid crisis

 

Epidiolex for Epilepsy Whitepaper

 

 

Πηγή

Thanasis Chalikias Προβολή όλων

A Product Manager with expertise in pharma marketing and sales operations

Σχολιάστε

Εισάγετε τα παρακάτω στοιχεία ή επιλέξτε ένα εικονίδιο για να συνδεθείτε:

Λογότυπο WordPress.com

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό WordPress.com. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Google+

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Google+. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Twitter

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Twitter. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Facebook

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Facebook. Αποσύνδεση /  Αλλαγή )

Σύνδεση με %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Αρέσει σε %d bloggers: